-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
Bo52QVwdL4tHjw1fHZjB/WNz7Xd+uT8gRljMXHi5cDXYWqsB2ZodH2bklKGGf7zE
eukVw+y6TRjv9pLv0NkqPQ==
0001193125-08-210224.txt : 20081014
0001193125-08-210224.hdr.sgml : 20081013
20081014171558
ACCESSION NUMBER: 0001193125-08-210224
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 3
CONFORMED PERIOD OF REPORT: 20081013
ITEM INFORMATION: Regulation FD Disclosure
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20081014
DATE AS OF CHANGE: 20081014
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: ABIOMED INC
CENTRAL INDEX KEY: 0000815094
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042743260
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-09585
FILM NUMBER: 081123198
BUSINESS ADDRESS:
STREET 1: 22 CHERRY HILL DR
CITY: DANVERS
STATE: MA
ZIP: 01923
BUSINESS PHONE: 9787775410
MAIL ADDRESS:
STREET 1: 22 CHERRY HILL DRIVE
CITY: DANVERS
STATE: MA
ZIP: 01923
8-K
1
d8k.htm
FORM 8-K
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
Date of Report: October 13, 2008
(Date of earliest event reported)
ABIOMED, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
04-2743260 |
(State or other Jurisdiction of Incorporation) |
|
(IRS Employer Identification Number) |
0-20584
(Commission File Number)
22 Cherry Hill Drive
Danvers, MA 01923
(Address of
Principal Executive Offices, including Zip Code)
(978) 646-1400
(Registrants Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Item 7.01 |
Regulation FD Disclosure. |
On October 13, 2008, we issued
a press release reporting our invoiced shipments for our second quarter ended September 30, 2008. A copy of the press release is set forth as exhibit 99.1 and is incorporated herein by reference. The information contained in this report shall
not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act
of 1933 or the Securities Act of 1934, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.
Item 9.01 |
Financial Statements and Exhibits. |
|
|
|
Exhibit |
|
Description |
99.1 |
|
Press release dated October 13, 2008. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Abiomed, Inc. |
|
|
By: |
|
/s/ Michael R. Minogue |
|
|
Michael R. Minogue |
|
|
President and Chief Executive Officer |
Date: October 14, 2008
Exhibit Index
|
|
|
Exhibit Number |
|
Description |
99.1 |
|
Press release dated October 13, 2008. |
EX-99.1
2
dex991.htm
PRESS RELEASE
Press Release
Exhibit 99.1
ABIOMED ANNOUNCES RECORD $20 MILLION IN SHIPMENTS FOR SECOND
QUARTER OF FISCAL YEAR 2009
- A 657% Increase Over Total Invoiced Impella Shipments During Second Quarter of FY08
DANVERS, Mass. October 13, 2008 Abiomed, Inc. (NASDAQ: ABMD) today announced invoiced shipments of approximately $20 million for the second quarter of fiscal year 2009. Invoiced shipments represent amounts billed to
customers for products shipped and services rendered to customers during the relevant quarter. The Company will announce its second quarter financial results, including its revenue, during the first full week of November.
The Company is in the early phases of completing its quarterly closing to determine the amount of invoiced shipments that will be recorded as revenue in the second
quarter of fiscal year 2009. It is still being determined how much of these invoiced shipments will be booked as deferred revenue. The Company believes that to the extent deferred revenue is recorded for the second quarter of fiscal year 2009, it
will be recognized as revenue in future quarters of fiscal year 2009.
During the second quarter of fiscal year 2009, the Company recorded total invoiced
shipments of approximately $20 million, a 75% increase over total shipments of $11.4 million during the second quarter of fiscal year 2008 and a 20% increase over total shipments of $16.6 million during the first quarter of fiscal year 2009.
Invoiced shipments of Impella consoles and disposables were $10.6 million for the second quarter of fiscal year 2009, representing approximately a 77%
increase over Impella invoiced shipments of $5.9 million in the first quarter of fiscal year 2009 and a 657% increase over Impella invoiced shipments of $1.4 million during the second quarter of fiscal year 2008.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a
leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow
and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding Abiomeds expected revenues and financial results. The Companys actual results
may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex
manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the
Companys filings
with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and recently filed Form 10-Q.
Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
Contact:
Abiomed, Inc.
Aimee Maillett
978-646-1553
ir@abiomed.com
GRAPHIC
3
g96690g00n17.jpg
GRAPHIC
begin 644 g96690g00n17.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`0`##`P$1``(1`0,1`?_$`+L```$%`0`#`0``````
M```````&!P@)"@4!`@0#`0`!!0`#`0``````````````!`4&!P@!`@,)$```
M!@$#`@0$`P0&"@,````!`@,$!08'`!$($@DA,1,402(5%E$R"G$C%QAA@;%2
M)#21H4)B_=UTZ[B6JM-.TQ/R@5J&
MJ94"K(`@B1!P[3%.;PNNY[MNRDV/M=]-`X6"ZMP3)*`.@$C*9`Z8^$-%#\BN
M3/`OD59,)5^*9KBKEWDW3LAO:37Z+DBJ.<'MR/+;499M6"$AY:-FV9
MO\(H8O6FL)=S=(&**O<-HV5N+8:N0+%;UVNXT-$]:"7`@SF<@LZ0)]F4X;"GYE[VN7..S/
MF[2+=PYJ>/K+1769Z;Q?G*':Y6T.<=(Q[B>BX"9R@C)H)$LTY7405,X33311
M7,4O2(;ZK#32E:TI!"YI*?X5!0G.;B$N#0H@2F21,"<7(<-N1<3RWXOX3Y(0\0M7FF7:-&6
ME2!_MJ.THN+-.674U"M*%(PR,CCA@,#/QB'&,,?9![CF7<<-YEHS0@U4W+EF(BN4Y!*(%ZO"J7)53SM0J
M0.M,DB6F4O&8RQ$NZ1^OVQQ)NO?3W*=)N=L"IJC<7Z`4;JZI#I=\Y3.I,T
ME.K#,F4Q(G&+CNWC@L>,7"[CQ@!Q:H6ZR>+L?QU=G;%7':3R$?3Z[EW+S?TM
M9`ZH#'-9-^HD@)AZC))@/QT@>S$LI`>X1G3E'6F6:^ZV&QUZC^EU5R_,2)A*TR40E8P
M"ATDJ8[H:SN0<9./G&6,XEY_X[8JH>",N5/F;Q_I4;:,6UZ,I3B6JV0K*,#;
M:S-LX0C%"R1$M$[E,W7*KT["(>9ATZ\9[PW1OQ^Z[8W%75%RMR;2ZX45*UNI
M;6G0H*1K)TJQ,B)8G.<,W)NU;%M!FV7C:E&Q;KHF[-(!82ELK;65)5@@#.8G
M(#K.&VXV\2L0]T/.W-SD+S983F9X[%_*?)W&?"&(I6V6:*QOBO'V)W#%@1W'
MPEYU3(=48V%]*N(*<2.0
M4'/HJ@11(!+M\XZ\=`53JC=URYFXEW`YOE+3^Y=M^0_3U>A
M(?6VXZEM2%.2"E`A>(P!D,"1.-#2YRHI&445]--(!445,?H*1-/YCG4.(@`$
M(4!$=QVV#Q\--)\P*2EH%3BI)`[3X=N$9:6I"`I;JM+:9K)R$AC(]P_LC,1Q
MV[X.0,K]RI?!%@1J#7BE><_=++3;KS>6TTL@9B8U:I8B8[8T\E-XCL8Q@+N'C^(>?F/CM_JUD[
MXM>LD>6H3`ZSEE&HD$$^4G45I,B3&>[N<]P;F]@7FKA#BOQ&B\:SLIF/'L5)
MPT)=J\F^>R5RD['98Q-LC..;'#,H]H#&%*;I5`"]6X]?CMK1W$_'>QMQ[)N6
M\-XNU#5-0/A)*"J6P0%`$S/B#AX0Q[_
M`+J_09Y*!/?<;>BB[@E#B47+AH^AK1:J](NXIH<72K
M!R5FNX03.*)Q,0P:D*N(.*=_T54_Q7=*G]7805^G>)R'_,2.R8]L,RN6^1=E
MWFGI^2*!INT/JTAUL``G#J)>Z-*+^RHJ460N,"]2?M%ZBZLT&\*)E6KIL:&5
ME8QT4HF*)D'"0D-Y@)BCK+-/1$W?].?\P.*?0TL3(T2.DR[">LNL:477J-L5
M=&BA3(84ZC_$"G4GV2BJ'LT6KFYNX^L7'UVH+?97'%(J*0.+U$GXB$GJ3AB
M8JKAG?=\W_27&JNR4)]/5^6@)D))^/L`[!#F=R#N=XUX"5R!B1@Y#*.=`*NS&7?[(
MK@A,D?J.LRQ2>2:Q0L$87@))$9*%QU:XRGQT[[%0!5:H/&=F?V&?0661$H[/
M'+)0-_F*F.K-K+?]+U@=%KJJJZUU3EY[9.B?;(.)F>T`15[5Q^I.\I-QI&:"
MCIAB&7`C61GU029],1"_XU]XC,]$SW#<2NYSA5+C[E&?<,6%6R?$)JQU!G';
MU8&L::6;+OY>-2BIEZ)4DI>-?N6!%E"IKE0\]-FZ^%K/<+`YO#B:N5Y
MF"UR=*Q+D^YP)FXS-3Q[=+-#BZ3,NT^I0->D9-@9RCUI>NU]TU)UE`P=1/(?
M'6?+33-5%VIJ)S66G:EM"YG)*E`*E/LG%^72L51VU^O9`4665+'82$S`\#&7
M+MQ=\GDSG'E1B7$_)I#'+3&N9/K-/KD_6:<[K!T,AHMD7$(B23<3K]!ZU
-K[9V-6;FV?4ONWFD;;6MIPDIT'YB!,X@8C`>,
M91XZYZW3?]UT]LW*PPU9:I]3:%I`!!$Y3,O?&LY0X@`]!S"8H#N'4(;_`#``
M_'S#^S?6+2XHR;Q"\%G^[PQR[HV`TA*EAPDZ4@I/9X^.'VQDW[DG?%Y-X+Y2
M99Q+Q@;8Y>XWPN6#JMJLEHISNSJK9`79N'Q23`IC&5;J
MCN(@.MK\4?3[M#<^T&+QNE^H:O%4AUU#8)`#8EY9E,?,D@GQC(O)/.NYK!NJ
MIMNVVV'+52K;;4H@$ZS,+QD>H/N';&H3$%EEKOBG&%SG#)EE[?0*;99@K0AV
M[09&?KL=)O!9H^LJ+5N#IT82$ZC])-@WUCR[4[='>*NV,%7IV7U!*IXR"B)3
M]T:BL%=4W*S4=RK`E%2[3I4I,L"5)!R^Z,P]7[D7>)Y"\A^2F(^*5%P7>66"
M$>MIFOQL*]CZVWMLQ7ZZ=P^G;S%(R;Q5.)-ZID@+N("/2'AK6C/&_"&V
M]L6B\;YJ:Y%1<&$K`;)Q)2DG\0R*OMC+M+R1S#N/<=WM6U6:5QBB>4D:DI.D
M!12)88SED3%D7"S('>;L.>X2+YH8DQ%4<"J5NRJS4Y3U*S]=0L:+1,]:00^D
M7RP/1;N'?457_#B7I\S!JLN1+?PC1V1"N/:JM?O&H:DNSE+KF3%D["N'-%3>
MBWO:GI&[1I/Q(2D&?24O[90YO=^Y@Y@X1\4F&9L*FJP6Y;*]0ISDUOAW,[$E
M@YN-L3Q^S<@;W19;VIU-&:92B$$B1"D#
MH1VYPY\R[QOFQ]I_J]G#?JR^$C4`9@@RS$HK:I_);]1%<:96LE5K`&`K+4K1
M7HJW0`H(5)LZFH&;CT)6*5(R4R)+AMR4QRWX7V+T_H>;.C;[VKWJ?PC^A=7T8>G^+_
M`+CK^[NG?_L?M?D]K_>\=M4/ZJRZOD5I]7_Z6GY?'5C_`&Q?/I[WH^8:O22S
M_P!75\W^7"<-[RXX>8YYAX]B*5=YBV4^=IULC<@8RR;C^4""O^-+Y#)*HQEG
MJTN9)P1)=-%8R:R*A#HN4A$IPVV$%VU-T5VTJQQ^A"5TK[9;>:7BEU!6EP@_
M\R<,#+LA'N_:E)O"V)H:U9;J&G-;3J0-3:A.1`F.V68B*5&[7)AREC;)_)7E
MUR)Y+<<84?*[JJQE$K]X0*8K*VO82L0[(L]*Q11W:>Y,)$#@!@`WB`S
MFZ1/(&W\DL29
M?XWU$F3)J!ELED9N+1C_`")4$7S&3CG43(-/\*[*8R2J0`(`("`EK$)\[!L*
M$AAB2,3-6'0S[._MCZ$WJAL'/6W[70SOC;F#C1Q:X7(9'L\',YZAD*9DG,&
M4B@Y>OXVIP$<<5EW*QQ]0Y=@^82E#T6D,LJ;4<9$XB727W#WX0
MR79.UN)N-KOM9RZ4=VWG>U--K%(5EFG:;6ES^84IUDD2Q0F8([(EOW>>4H\5
M>"F7;8P?E87F^L"XFQZ*2F[@+)>6[EFZD4"@'J&""KB;UZ8Q0W**)?$!'4ZX
M.VF=Z\CT5(XE1MM(HONJE/X6QJ!E.1FK2)=A\8PCS1NG]J[!JJA)";A529;3
MJD?C,B9]R)X=I`C.UF[A%_![LN\8LUUEU'1F>L29&B^3-A5;/8\T_'QN67D6
M@R;+D17,^%2JLHVM*F2\0(HV5'XF'6H+%O4;@YRN]E=9JAM:O8-(VEQ)"4FF
M1I#FG%(UZ5$8Y$"<9RW+LE&W.&[1>FW:<[DHZCU"EMJ!6M+ZRL))P/PA0![P
M>V-8W#GD)#\J.,V&L\PZA!_B#1XJ2F6Z8DWC;2S+]+M<6H0IOW1V-A9N2`40
M`W0`"(!OK%^^]MKVCNZML[P)325"TMYS6V2=*B#E-,LIXQK?9.XAN?:]%=DD
M^8_3H4O*25@`*3/J9S/A&;/O*Y;7P'W<^&&96]-F\BK8[QO5[,G1ZSZ@6"SK
M-;C?T$X>)%-H_,+U<%A,4`14'I+Y:U9P59QN'A/=%F?>0PR\\DZU@20=(D9=
M0)XXC*,TD$C5(93&(F,/&41.[FWP#;L&
MV;B'BM?)$38[3D++C:Q2[LKHK=Y!@^0:,:G%F+#5V,F73IP5O[ARN<"!L0A3
M",TXS$>,;(:Q'UF-XV0,93)]K:JA&8391E8LS)PD\9V&OQM&(S
MB)IJZ1.HBLC)LD$URF*80$#ZP^]4U[^Z55-:V:>M5<2M:")$$NS*3/$2)^SO
MC95-;Z"GVCY-,L/TK=OT)4#,*"6I:@>_[(HA_3/EZ^./)0`\/_L"WW#\0"EQ
M&^^M$?5LVI.X+6&@"HT.GL^4MC5XGL[XHOZ8TE-KO$E$`7'_`-S"&DX?5:,Y
M==]OF#E7*B))X>,IYUGC.`F4R.&T4[JTTUQW4'R$>YZD]H!F#YXCL39%Z[*J
M'SB!M/N^ZUS9OT[V.P[>G3*NFE52XC-R:2M0.6!)(E/+"&K9K+>\N>KK7WA*
M:BFMP4&M7X2%!*9#+"7V"-5Q$?E`1'_]@.EY)X%W#*,HT;I7K!,W6[33["!4D9)!C-S
MT;7;%7TW>P*'8R[:2(MZ/B4'+5)0`ZB[ZOWZ<=QUMLY%8L;94+9=TJ8>;F2@
MA*24JTY3PEX$Q0OU#;:M]UV,N[R";I;%!QMS\4B1-,\Y9'/,0_\`Q=RG9,S]
MH6HY)N"ZKVS37$2[,YE\Y`X+R#VN5*S5D\DN903'.M(A#%64,(B)C'WW\=1?
M>5E;LG,57:*,Z:%F\("`!*0\P?WY1)=J7EV[<1LW*K^)]5M5KF?F(1*>C!R31C*@!?R
M^V5-\=;*O6\*>CYR&U;O)5CO%H;96@X(0N14EG#VT4N>JB[;TBX5^X58T3(]7\52(&
MK!JH9(AAZ5E+_P#N`((;@D;?;8=8X?^H%L*4G$L)).L#_@'
M0RGUC77]1J-KC#]^)*3KI!-`5@'R!-.J4YZI](R=YX-/6+#V3LNIY%RS:(9LVQJT;N%8`
MT!DFXO57,T=RF8B2#WWI"(FW#J.0P:W+O#C*X[3;M]9;Z%='1`?]PI2?
M,U--XS"%8C3]N<8XV1OVDX\WON9RMHJRI0[4J_\`CR5IDXLXS4F4YYQ?QPQ[
MQE)YD9XB<$0?&S.F-)&5KMAL*=NO;"/0KB"5=:I.E63A5N0IP=/"J;)!Y"8-
M9DWWPU6[#M8NM3<[;5+4H#2P5*5B>]*8T+L?F&CWK<_TNFM=?2I`^9W3IP\"
M9>^&=_4=^';WCCB!1'^8#'?@`>'C!7C??^GPU-/I143RII09)-`[T_Q-SB+?
M4XPIWCM#CBI*17-REV$*E%KG#8HFXB\81#\PX!Q'M_51X40`1V'P\=4;O@.)
MW7)]"ZA8B?9-GS4NX^@J0QB[=1M[X^E
M:^5=/O9S:&L_H]73E2T+^-$QA@%89$@X=D4G]2%CI7]IM[I4E)N=*^$I6GX5
MD''$C'"1P[X=O^>W+GT[ZA[C_P#&G^;ST_3+_P#+?W3]L_5/R_E_ZNWEID_I
MO9?4>3YAE^\?03TC^5Y/FZ\\_P`.G*6,X("`#N`>/F.X[AY_AH)04D*P3(P?'JU
M`G3_``@#[XRC=TH'O<.[H/&KMWUF8?M:#C)HM9LLR,2=$5XM_/1Q9^V227N$
MEVII*M41@V:M_5(8$WDF8HE\1`=<\/J3Q9Q97\HU*4+K:M(9I$'`J1/2"<,)
MJ2>^72,@N6';GRDY!M;<*7RP6^HLE]D@5:(3):W>T8PIAV,Q6>IQ\LD4NX>E(F/X
MAN.G_P"H^VT>X*6UP9P@^Z%>Z;C;O:\`\@WZRQ=0I54I
M]/E[+9YMQ[**@XA.VY"36?2+@Q1]NU(HJ4!,(;`([?CI5Q!05]TX*W/26EAQ
M^OJEI0TE,@5$I$QB1T,\90UD$Y]@,/)
MW@^XGV_\I<)LDXQJ64J)G/)5P)$M,<15.`\Z\JMD;3+-RG=5I@&16\*G%-T%
M2CTJ`LY]4$2D.50=-7!G%W(]@Y&H]QUU/44%II`KSUN+2$%&DB13K).,NDL)
MYRB17S8]79Z&HIJV[U.D,(;2HKU:AB#IE@)YD9Q/GMC4+(.-.UIABI
MY-;R,?9FV([G*IP\L19.1@Z]8'-DG*M$NT5R$6;J-("0;[)&`!2*8";!T[!6
M?*%RMMWY;K*RU`>F7<``1*2E)<`*@1A(R_V,6'QO27*W<2T]/>`4U::%>!S`
MTF0(Z$#//QBO?]-`._'#DMT@)A+R";_DV^4?LJ'$!\?`=@,`B&K6^K'5^Y+3
MI$TKHU&8Z).@A7W=^,5O]-!'Z/>5YRN$QW_S(:+FA#9,[47TD&U1(P@WI56J:+Q=NF/V77EP&1D9%0J:+E5NB@W]01'?1'%NR6^'V
MJGDCD5`I+BTR11TZR%+*R/F`05`*4,`#+`F9G&>^3-[.XZE
M50^@*2F0_#-822$SQP[^R+^G6&Z]QVX#V/!]8,)X+%_&2W4UFZ,42C(*Q6/Y
M5&0E52B8W2I+2(JN#@(^!E1UF]=[K-R\A(OU0)O5MS0ZJ7X=3@D/<9>R-"55
MFI-L\>KLS!`:I+8I'C)`!/M/WQ4#^G3J<%=^WOFZEVIBE)UNVYCNU9G8QRF5
M1N]AIJ@52/D6IB](@8J[5T<-QW\PVU<_U,U#UKY.I:VD,JMFB86)=""3TPZ"
M*=^G&FI[EQW64%4`:9=0L&?8H$3EW??%)#O'7(IKDP_9`1M
M8SQ2B*,Q?)NP1$@$"!^V"FGQ4W`@OM_#J+X:*55[?_0F_J)2XVJZKLOE%((_
MGD))`&>L$*3/+OBAUTU__7U<(A"S:4W;S)RPT`J`,\I$$$^$7@_J&JI`4'MR
M8BHE58)1=:IN7,?5>!C6Z8$39PT%1;3&L&P$3`";IM&H`.P>([_'5`?2W655
MVY/K:ZH*E5;MN=6LJ(GJ6I)..7;D8OCZDZ6CMO'U!;*4!+2:QM*`!T0D@^[O
MB]SCD<`X^X(V\=\/XS+X!OMO380-Q_HWUG'_S%8>V+\V@4
MN;:HG$D%!I&I?Y!&6OM8\EN/_&[G?W+I3/N5J/BR-L^29=C6W5UDDXU"9=1^
M5+JH^;L3G34]=9J5TF)P#Q#K_;MK;EG:VZMT<>;0&VJ9=6&Z(>9Y8(*26F@)
MSTSR,I3$94XJW/M;:N^]S.;BJTTR7*@Z?,F9_F*)E+5]O2-(^(N<7#7.MW:8
M[PUR!Q7D.^/H^0E&=8JDR@^F5XZ+2*K(O$T$T$S>@T2.`J#OX`.LQ7_8&\]N
MT0JMQ4#]+1D@!2R)3.62B?LC2]BWWLR_5AI;#7L5%9+%*`0?>4@?;%8'ZCXY
M?_7Q%IAN)C9^QSTD*4PB.T'=B^0%W\SA_IU;_P!*;K+'*>M1_+%"L3SQ*D2&
M$\Y15GU,.)_IT$*(#AK$&4^@"IGV3A]N,O
M^X!R^D.\7E'%G!3A'!6&R8P8WF/M63LK/8>0CH,R<>)V7UYPB[*DK%4^J1SU
MP[!9X"2\B],DDBG\@]5T<<[-3P=15._N05--73TY2Q3ZT*62<9?`5#42$@8@
M"*:W]NQ[F2XTVS-CMN.6D/ZG7]*DHS`G\0!``F^Y^?_B\?/67/WS>-6N2M7ZOZ[/\$:5_
M8=JT^7AH_2?0Y?@U:_\`JZ=L30U$8G$&B"#1!'@?(?V:()RQB)^..%7&C%6<
M+YR3HV,V$3FW)WU8MUO[B2FY:7ERSK]I)2B9$Y21=L8]-VYCT`,#=)(`22*F
M&Q0VU):S>6Y[C8VMM5=0%V1@@H0)``B8&0':91$*/9VV*"^+W-2T^B\N@A2S
M.9GGGVQ*D`*`@F("(B`_#Y0V_'QVU$EJ:\T-R,SUZ81+TI7H)41X>,158\)N
M,D5R2>7
M4$*7VI)!(]I`A*WEP_P"65RB<@\@<01^0;="5\E6C)9Y.6:-4;0)'KN0)
M'@UAYB/:'3!X^54ZS$$^YQ\=.NU>1-Y[0MZK?8*U3-&M>LB0D2,B<,Y`"&K<
MO'6T-U5(N%\I2[5@:9@D8=D(;&7:@[>F(K3'W>D\8-]A0=LVEIDY9@DZ1.`&(?TA,0X`8H@(;Z=[MS1R5N%A5+775]3:P0L(_+U`
M]I2`9>V$5LX@XYLCZ:NDMS*7$&:2HE(M>LU5X]8^98[@+A8/NBQ1S*3F9,DA.@S18`
M^.K-2$@LF8&CL'Z+AJY05*/B4Y3!^&PZ9&:FX4%4BMM[ZF'4&84DR4#T((RARJ&:"YTB
MK?Y*<`D
M=,!%A;>V?MC:S018J%JG`_A&)QS)Q)]\/;9*[$6NN355GFA7\#9(B2@)M@H9
M0I'T1+LUF$BS.HD8JJ97+5(]+D<==7LLC#LWTK)).
MIQRT:,5GQUYA\_<$,9LQ2+TE,!``@;`&GO<6Z;[NZK%RO3_FUB4Z)X?*.@E#
M#M[:]BVI3*M]H9+=.XK41VF/H'BO@(W(8O*H<V]U],%;VO[D''H^N"(B0#@41#70[EOPV^G:@?<_0D*U!$\`<_OF?&/4;9L
M";\K<)IV_P!94)%R/RY'\6L$7*K?K:ZB0Y5/JU*)409DS)$B)3AQL#=LWA%QGR,PRY@_"$11<
M@QD5*PK*Q,YRUOUT(V;1*VE&P-Y:;?-#%=($`HB)!$OF`AIDW-ROO?>E"F@W
M+6KJ6`09:0,1X`0Z[=XPV9M>N-?8Z5+501*843]Y,/OR&XQX3Y5T9#&F>Z4U
MR!1VL]&V=O".W\G')I3L2D[1CWX.H=['O!4;)OE0`/4Z1ZO$-1O:VX[WL^Z&
M[;>=%/4E`2#*9&,\B".@AYW-M6Q[LH1;+^QY].%E6'^/&$N/U9/4,(XOI.+J\H*9G,?38!C$@^42+TD
M6DG228OI)=?WWZI>.+BR1CV">`]D6':-N6;;-
M/Y&W6&:,=2E(F9=I,R8>S;^S;2&'O&/.B"#1!!H@CP;Q`0#S$!V^'P_8.N""
M00,Y0>.40RQ=S/Q[DNXQE13J]_IS:S?Q75H]MN,=!M*M=$\*6,U9R,I'/8V=
MDW,26%>D]0GU%%F#AMNHF(](AJ15VTJ^T4:%K>;=>5Y.I*$G4DU#?FMX:0#J
M3/+(X=8BEIW?;KS4.,I;4VAH/'4LB1\ASRE_BZ'MAZD<[X4=TZ4R`AEK'AZ/
M"20Q,O;T[A!_;L9+$403^F/I@'H,T7Z@N$^A$Q_44!0HE`>H!%F_2:]#R*?R
M7B[\2D@I(F`"#AV`G'H#WPZN76@=HU5'GM);!2E1!&!)!3CVE(Z=(^TV9L0)
MRU2@5LGT1.>R`R;RU'AE+5#DD[7'/""=B^K[`SP',HT?$W]`Z13%6V'HZA`=
M=*6@K5LJJD,NZ`9*,CI"D@A6.70D^\Q[O7*AI_R':AM+JA,8B>E9!3[YB4=1
M+)V.%VK&02O=2.PDV]B=1CT+%$BUD6M1.XVJF>2IM(4?A,PGM(Z#O.$>!N]L+*"'V5APZ1D03+IWQP67)#$
MS2O!/WBXUS&:![+;JPT1OUKJ40L_<4ZR.*S(NV:J$X[9K-SO42&Z?4!9`JI2
MKD24W("AVR7)=3Y5.PXX4H;4=*20`ZC6GVR'WPF;OUO;IO,JGDM36M*=1E_+
M5H5+VD>^%;8.S%31,0HE5./23#3=36NOJT*(
MZ8RDE+/F@)O9(+"06Y2`;<$3B;8`WTNMVV[A+3K0AQ]H/J2D@3&.K*7;/I'.;9JQ`[^\#M\GT-8N/5?2O?1:X
M7IIQA<*-`^Y1]Z!88H.TC)"9QT%!4HEWW`0#JBW7)TLEEETIJ#\`TDE6$SI,
ML9#H,H[JN=M9\[S7FPJG^?XI:1.6(]O9G"6C>37'V9NBU"B\NTA_:D*$UR@>
M.;6%FH@>@/E9!-M:DI`BHQRL48L2X4$Y51Z$4A4,`)[&%1^WKPU3IKS2N)96
MZIL$SEJ3F`GH?9VB$_[ALSE0JB]2@OMMI<(&!TJR,P!,=T_9#JU"YU*_P#.T
M4FQ0MLK1K4W:H]_/LGLJT?>TD(R"5%(K=-PNH004
M*F*0'.7U:M536(-0XRM*D-J63(_A*4RF.]7@#G'5VZTS*@TEYM6IQ*!C/Y@I
M4_";A:7DN5##[2ICS,Q()&!/
M'C7*Y&ZKAN03
MIE/L)B[P\=>=31W5AUI%2TMIM]*PE2@0)A2`)'NGC"EBX6I;;SM.XE9IT'
M4$G(]X[<(9S%W*FAY.AJO8@;OJ;#VVBQ]Y8R-KDJXP9-T):[NZ#'PC@"S!WX
M2[V;;$!`?0]LJ#A-,JOK#Z8/UVVW46VLS'B6GMG#JU9+HM>;-;!]K.5YRTP\:FWL
MOMD'@P"YWCQ($I_\`;.GJ]?\`
MR_\`S-O^E_SO]W2:4./MCM:XCF#1!!H@@'P\=<$R$X(J&9]M!S%PEC9P5UAH
M">R?0>5&.\K6-@A8W#B8CLYWM_>L?S,$R?R)FL/,4AXZ]M(@T,R+(M%5"=0B
M5(0L9ODE50ZTJH;`:972+0G2")TM/Z?$D?C3\0A=*\E91K<4E[2VI`\
MR>(&.H2ZB64*#(/#/)]^N%UDUYO$49!9EF..MER!(I0UD?77&TM@AU#/!AL/
MO5$V[8U?G5*\D9DJ]%H:,6=.U@16%;I#SM^]J&W,TQ::>6N@%0E(4!I?%1J!
M4\!^).K#3.3K(F0V,96)GPX[R=:HK(V8B.%DG2/O&%YOD*@8Q6GMU$H
MM1=$!^8`UWH^0?3LT,V0I;#C:UJ(Q<\II3+0/_"E949YJ`SSA+4\=NOJKG4O
MZ14H<0E()DCS7D/*(]J-(_PD]85-"X/.H:;Q+:K*VI*,_3,X6+,EV8I6"]9)
M8V>2>XE=XP@9&,D+^W*[BIV-3.W5'I2(BFF@&QCJ_/IOJ=ZE2ZEL..*344P9
MQ0E&D:@HX([Q]IZ0Y,;'4AJG4E#32F'_`#<%*5JP(D=4\,?NCFQO`B7`&83L
M]19I!E%.09HR51+D_4KCJ$I^+
M\[T52'GH@90SF2R]$0$.SDFHJ`HU0;Q:,.J5QN3U3I+`!1_,&H;:=P^AM3U$
MQ,!VH9<*A,&3).'?JGE$UNVW_7W5FLJ`D^53O("3B)O#,]?A($B/'.41+KW;
MXM$/?,:SJY#4OC3!6U@_MN1ZNYA[)QUBT&49-U:/KRIXJQ,)-VV3?(
MM94Z`MW0&$QSIJ&*,KJN0*:H8K4M-.M$OU"V@&VU!0?420O5B)3E\,P1GTB$
ML5;3U$77&79,,H=45K!264@`IEGJZSE+I"=6[?&;+4ZSW)9*RC0['*Y@Q'
M,XH^LK-[:[)))N\O(Y#CI:9KSP$X2`C6%92^F!&1B0(E4**HG4%0XZ2_OVDM
M]';&J1+H31N!R1;;$U>44*^),U*F2535VRP``A9$XR%P'/46SM9V&!-6'EK`_A"
MQ[VJ-2JMZS+L+*JU?%(9-TV313,W$0$2Z86=SH2H8S\P#5
MJF
M;E3KC`0K*Y"^>`E/N;-&^^L35?'57C)UX@R&>AJI5169O'\BW))/EB(G$`V.
M(MUYK;?<'E5:0ZETRPTC2OI?&KR`]LT5^H1C,J1F
MKMTBV65V]P19(.C7MMB\6^AIGC5.58G_`*0"?+8WE\DL,#NF3*;G%WE?)-V-#2+0UUAXS$=KPO1(%@@=91=F
M[KU.D(P#G4,*9UT71RANMI._O5ERNJC2L!NEJ:0M)1+!N:TK*AWE0.Q
ML@L6^F;4Z7*NFJ@Z3/\`F?"I.E78!JZ=D-A+]O=W6,J\E/P[,:MQ$L6$YY
M2BTR0EI2V60,DU;)D;)FK;0[1>U0CA6O.&;J.44]RZ3?K$(8/4-NZT^_U(N2
MJYYM+@D$3D/C)P_A':8;*C8!7;T4;"E-%N@73ZDG%6I:%ZS
MVJ^`#'H3V`0[G!^HY$-;.4^6+S3&-#;YBNN/#UB,84R;H#9]'TG&,14GTVUJ
M5GZ+0S8.99-8B2T@DW<."HB)4P2!,3(MY7*T^GMEKH7W7D49=45+TE1+BDJT
MDIP,M/LG'ML^T7=0N=56,-TZJTCX4E4A+4)I"O'K"9K';ZD4:.K1[=<8&304
MXI&P(1Y&QT@@YCKBTRE-9,KE]CS+G,*:-?DW;)5`FX+`Z:"8!`-M=7M]%5X_
M5VV4A8N7JM$BI!FG26R3B1*<+4[%'Z>JB6X%%RB%/K."DR)4%`#"[OA(6
M?MV7J8JF*5WUXJ]SR''1V9"9R-*2U[H-:R?8L[.85_=K1&R%.]Y/Q:K0T&FP
M;LEDU458D00$Z8IE,*^WV"XS9;QSFBP9,Q#+8Q
MIT*^Q0RJ)JS)R%[L#"_7.NU2NU6AV*],7I`^A!3V$*+0[R)J6I+ZEZ@E"2`HDJ2",YX&2A(&Z*YJN-'Z-N;(
M;T:G%##)7Q`F?WQ.GJM'GU5[;[>_N2._W/MMOY_^/]?P_P`QM\=0_P"'M.?V
(?WQ/Y'[(_]D_
`
end
-----END PRIVACY-ENHANCED MESSAGE-----